drug
Imatinib Mesylate Shilpa
Marketedupdated 3mo agoby Armas Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for chronic myelogenous leukemia and 55 investigational indications.
all catalysts(46)
approval · 46
Apr 18, 2003
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
May 20, 2003
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Dec 8, 2003
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Jun 23, 2004
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Mar 14, 2005
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
May 18, 2005
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
May 19, 2005
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 20, 2005
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
May 31, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 27, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 19, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 19, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 19, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 19, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 19, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 30, 2006
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 13, 2007
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Apr 30, 2008
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 26, 2008
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 26, 2008
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 26, 2008
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Dec 19, 2008
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Feb 10, 2009
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
May 27, 2009
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
May 27, 2009
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Apr 1, 2011
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Apr 1, 2011
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Jan 31, 2012
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Jan 25, 2013
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Feb 21, 2013
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Oct 30, 2013
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
May 22, 2014
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Jan 30, 2015
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Aug 25, 2016
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Aug 25, 2016
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 27, 2016
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Apr 24, 2017
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 6, 2017
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Sep 29, 2017
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Aug 21, 2018
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Aug 10, 2020
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Aug 10, 2020
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Mar 24, 2022
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Aug 19, 2022
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Mar 1, 2024
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Jan 14, 2026
approval
$NVS150.88-0.55%
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Trials studying Imatinib Mesylate Shilpa
- phase4Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
- phase1A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- phase2Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host
- phase1A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
- phase2Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 27, 2040
~13.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Apr 27, 2040formulationUS 11957681
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that